Melanotan II raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid in a sealed vial |
| Solubility class | Soluble in water and polar organic solvents | Reconstituted solutions are generally clear |
| Typical storage temperature | -20 degrees Celsius or below, dry | Protect from light; avoid repeated freeze-thaw cycles |
| Common analytical methods | Reversed-phase HPLC-UV, LC-MS | Used for purity estimation and mass confirmation |
| Reported purity range | Area percentage above 95 percent | Reporting practice and acceptance limits differ by laboratory |
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
== Bioinformatics == Owing to the increasing complexity of regulation of cellular processes and the roles proteases play in them, bioinformatics continues to be an invaluable tool for degradomics. Software, databases, and projects developed for this purpose have accompanied the advancement in technology. Software developed in the Overall Lab (CLIPPER) statistically evaluates cleavage site candidates determined by degradomic approaches. One web-based data site, WebPICS, incorporates and integrates cleavage site analysis from PICS experiments into MEROPS, the protease database. Another database, Termini oriented protein Function Inferred Database (TopFIND), serves as a knowledge base to integrate protein termini formed by protease processing with functional interpretations. By combining research literature and other biological databases including UniProt, MEROPS, Ensembl, and TisDB, the database comprehensively renders protein termini modifications accessible to a broad scientific community. Using TopFIND, terminal modifications can be identified and visualized across proteins thanks to all available in silico, in vitro, and in vivo findings. Using TopFINDer and Path FINDer software, research findings can be mathematically modelled into a network of pathways regulated by proteases, further contributing to the “protease web”.
=== Early research === The ability of palladium to absorb hydrogen was recognized as early as the nineteenth century by Thomas Graham. In the late 1920s, two Austrian-born scientists, Friedrich Paneth and Kurt Peters, originally reported the transformation of hydrogen into helium by nuclear catalysis when hydrogen was absorbed by finely divided palladium at room temperature. However, the authors later retracted that report, saying that the helium they measured was due to background from the air. In 1927, Swedish scientist John Tandberg reported that he had fused hydrogen into helium in an electrolytic cell with palladium electrodes. On the basis of his work, he applied for a Swedish patent for "a method to produce helium and useful reaction energy". Due to Paneth and Peters's retraction and his inability to explain the physical process, his patent application was denied. After deuterium was discovered in 1932, Tandberg continued his experiments with heavy water. The final experiments made by Tandberg with heavy water were similar to the original experiment by Fleischmann and Pons. Fleischmann and Pons were not aware of Tandberg's work. The term "cold fusion" was used as early as 1956 in an article in The New York Times about Luis Alvarez's work on muon-catalyzed fusion. Paul Palmer and then Steven Jones of Brigham Young University used the term "cold fusion" in 1986 in an investigation of "geo-fusion", the possible existence of fusion involving hydrogen isotopes in a planetary core.
An yttrium–barium cuprate, YBa2Cu3O7−x (or Y123), was the first superconductor found above liquid nitrogen boiling point. The three different metals in the YBa2Cu3O7 superconductor are in the mole ratio of 1 to 2 to 3 for yttrium to barium to copper, respectively; hence, this particular superconductor has often been referred to as the 123 superconductor. The unit cell of YBa2Cu3O7 consists of three perovskite unit cells, which is pseudocubic, nearly orthorhombic. The other superconducting cuprates have another structure: they have a tetragonal cell. Each perovskite cell contains a Y or Ba atom at the center: Ba in the bottom unit cell, Y in the middle one, and Ba in the top unit cell. Thus, Y and Ba are stacked in the sequence [Ba–Y–Ba] along the c-axis. All corner sites of the unit cell are occupied by Cu, which has two different coordinations, Cu(1) and Cu(2), with respect to oxygen. There are four possible crystallographic sites for oxygen: O(1), O(2), O(3) and O(4). The coordination polyhedra of Y and Ba with respect to oxygen are different. The tripling of the perovskite unit cell leads to nine oxygen atoms, whereas YBa2Cu3O7 has seven oxygen atoms and, therefore, is referred to as an oxygen-deficient perovskite structure. The structure has a stacking of different layers: (CuO)(BaO)(CuO2)(Y)(CuO2)(BaO)(CuO). One of the key feature of the unit cell of YBa2Cu3O7−x (YBCO) is the presence of two layers of CuO2. The role of the Y plane is to serve as a spacer between two CuO2 planes. In YBCO, the Cu–O chains are known to play an important role for superconductivity.
With a reduced response to insulin, the beta cells of the pancreas secrete increasing amounts of insulin in response to the continued high blood glucose levels resulting in hyperinsulinemia. In insulin resistant tissues, a threshold concentration of insulin is reached causing the cells to uptake glucose and therefore decreases blood glucose levels. Studies have shown that the high levels of insulin resulting from insulin resistance might enhance insulin resistance. Studies on mice with genetically reduced circulating insulin suggest that hyperinsulinemia plays a causal role in high fat diet-induced obesity. In this study, mice with reduced insulin levels expended more energy and had fat cells that were reprogrammed to burn some energy as heat. Hyperinsulinemia in neonates can be the result of a variety of environmental and genetic factors. If the mother of the infant is a diabetic and is not able to properly control her blood glucose levels, the hyperglycemic maternal blood can create a hyperglycemic environment in the fetus. To compensate for the increased blood glucose levels, fetal pancreatic beta cells can undergo hyperplasia. The rapid division of beta cells results in increased levels of insulin being secreted to compensate for the high blood glucose levels. Following birth, the hyperglycemic maternal blood is no longer accessible to the neonate resulting in a rapid drop in the newborn's blood glucose levels. As insulin levels are still elevated this may result in hypoglycemia.
Sources: en.wikipedia.org
== In research == In her book, Becoming a Stepfamily, Patricia Papernow (1993) suggests that each stepfamily goes through seven distinct stages of development, which can be divided into the early, middle, and late stages. The early stages consist of the fantasy, immersion, and awareness stages. In the fantasy stage, both children and parents are typically "stuck" in their fantasies or wishes for what their family could be like. The developmental task for this stage is for each member to articulate their wants and needs. In the Immersion stage, the family is typically struggling to live out the fantasy of a "perfect" blended family. In this stage, it is critical for the "insider spouse" (i.e. the biological parent who typically forms the emotional hub of the family) to understand that the feelings of the "outsider spouse" and children are real. The task of this stage is to persist in the struggle to become aware of the various experiences. This stage is followed by the awareness stage, in which the family gathers information about what the new family looks like (e.g., roles, traditions, "family culture") and how each member feels about it. The tasks of this stage are twofold: individual and joint. The individual task is for each member to begin to put words to the feelings they are experiencing, and to voice their needs to other family members. The joint task is for family members to begin to transcend the "experiential gaps" and to try to form an understanding of other members' roles and experiences. The middle stages consist of the mobilization and action stages.
The 2013 Essendon Football Club season was the club's 115th season in the Australian Football League (AFL). This season also represented the first time since 2002 that the club independently competed with a reserves team in the Victorian Football League (VFL).
=== Legal status === The United Nations Convention on Psychotropic Substances of 1971 mandates that signing parties, including the United States, Australia, New Zealand, and most of Europe, prohibit LSD. Enforcement of these laws varies by country. The convention allows medical and scientific research with LSD.
Sources: en.wikipedia.org
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.
Most certificates state a percentage derived from chromatographic peak area, alongside a mass confirmation. The exact criteria and acceptance thresholds vary between laboratories.
Dry powder is kept frozen or refrigerated and protected from light and moisture. Solutions are handled cold and used promptly to limit degradation.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.